The effect of dexmedetomidine on the sedation during the radiofrequency ablation of hepatic neoplasm
Not Applicable
Completed
- Conditions
- Neoplasms
- Registration Number
- KCT0003229
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
1. Patients who undergoing a radiofrequency ablation therapy for hepatic neoplasm
2. American Society of Anesthesiologist physical class 1, 2, 3
3. Platelet count > 50,000/µ
Exclusion Criteria
1. Bradycardia (heart rate <50)
2. Second or Third degree atrioventricular block
3. Hypersensitivity of propofol, dexmedetomidine, remifentanil
4. End stage cardiac / renal / hepatic disease
5. Abuse history of opioid or propofol
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method respiratory tidal volume of patient
- Secondary Outcome Measures
Name Time Method vital signs(blood pressure, heart rate, respiration rate, oxygen saturation);level of sedation;satisfaction rate of patient;satisfactio rate of operator